[Abstract Only] Randomized trial: Carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma 22 Jul, 2020 | 02:11h | UTC Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study – The Lancet